Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy
Abstract Background While many studies of effective hereditary angioedema (HAE) therapy have demonstrated improved health-related quality of life (HRQoL) using validated instruments, specific reasons behind the improved scores have never been investigated using qualitative methods. A non-interventio...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-06-01
|
Series: | Allergy, Asthma & Clinical Immunology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13223-021-00550-5 |
id |
doaj-aed4064836e946e98087be2e6fa6d3c6 |
---|---|
record_format |
Article |
spelling |
doaj-aed4064836e946e98087be2e6fa6d3c62021-07-04T11:48:13ZengBMCAllergy, Asthma & Clinical Immunology1710-14922021-06-0117111310.1186/s13223-021-00550-5Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapyJohn Anderson0Donald S. Levy1William Lumry2Patricia Koochaki3Sally Lanar4H. Henry Li5Clinical Research Center of AlabamaUC IrvineAARA Research CenterICONICONInstitute for Asthma and AllergyAbstract Background While many studies of effective hereditary angioedema (HAE) therapy have demonstrated improved health-related quality of life (HRQoL) using validated instruments, specific reasons behind the improved scores have never been investigated using qualitative methods. A non-interventional, qualitative research study was designed to investigate the reasons for improvements in HRQoL while using effective prophylaxis, in this case subcutaneous C1INH (C1INH[SC]) replacement therapy. Methods Adult patients with HAE-C1INH type 1 or 2 who had been using C1INH(SC) for ≥ 3 consecutive months were recruited through four HAE specialty practices in the US to participate in a 60-min phone interview performed by a trained qualitative research specialist (ICON plc) using a semi-structured interview guide with open-ended questions developed with the Angioedema Quality of Life (AE-QoL) items in mind. Interview transcripts were analyzed using thematic analysis methods to identify concepts (specific symptoms/impacts) and themes (higher-level categories grouping related concepts). A cross-mapping exercise was performed between interview-identified concepts and items included in the AE-QoL. Results Fourteen patients were interviewed and included in the analysis (age range, 28–82 years [mean 47.5 years]; 64% female; 93% white). In 10 interviews, patients mentioned having no or nearly no HAE attacks, no longer feeling limited by HAE, less HAE-related anxiety/worry and depression, an improved ability to travel, fewer emergency room/hospital visits, and ease of administration of C1INH(SC), including not requiring assistance from others. Other commonly expressed concepts included: increased feelings of confidence, independence, optimism, and normalcy; less absence from work/school; better productivity; improved sleep and energy; healthier family relationships; and improved cognition. While all AE-QoL items emerged from patient interviews, a number of identified concepts were not addressed by the AE-QoL, including sensitivity to various potential attack-triggers (e.g., stress/anxiety, sports), attack frequency, not having to cancel social plans, improvements in ability to perform day-to-day tasks, and a lower burden from medical visits. Conclusions From these interviews, a large number of common themes and concepts emerged: a greater sense of freedom and normalcy, increased productivity, and improved interpersonal relationships while using convenient and effective prophylaxis. These findings provide insights into real-world experiences and the many facets of HRQoL that are important to patients with HAE-C1INH.https://doi.org/10.1186/s13223-021-00550-5Subcutaneous C1-inhibitorHereditary angioedemaHealth-related quality of lifeProductivityHAEGARDAQualitative research |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
John Anderson Donald S. Levy William Lumry Patricia Koochaki Sally Lanar H. Henry Li |
spellingShingle |
John Anderson Donald S. Levy William Lumry Patricia Koochaki Sally Lanar H. Henry Li Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy Allergy, Asthma & Clinical Immunology Subcutaneous C1-inhibitor Hereditary angioedema Health-related quality of life Productivity HAEGARDA Qualitative research |
author_facet |
John Anderson Donald S. Levy William Lumry Patricia Koochaki Sally Lanar H. Henry Li |
author_sort |
John Anderson |
title |
Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy |
title_short |
Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy |
title_full |
Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy |
title_fullStr |
Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy |
title_full_unstemmed |
Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy |
title_sort |
letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous c1 inhibitor replacement therapy |
publisher |
BMC |
series |
Allergy, Asthma & Clinical Immunology |
issn |
1710-1492 |
publishDate |
2021-06-01 |
description |
Abstract Background While many studies of effective hereditary angioedema (HAE) therapy have demonstrated improved health-related quality of life (HRQoL) using validated instruments, specific reasons behind the improved scores have never been investigated using qualitative methods. A non-interventional, qualitative research study was designed to investigate the reasons for improvements in HRQoL while using effective prophylaxis, in this case subcutaneous C1INH (C1INH[SC]) replacement therapy. Methods Adult patients with HAE-C1INH type 1 or 2 who had been using C1INH(SC) for ≥ 3 consecutive months were recruited through four HAE specialty practices in the US to participate in a 60-min phone interview performed by a trained qualitative research specialist (ICON plc) using a semi-structured interview guide with open-ended questions developed with the Angioedema Quality of Life (AE-QoL) items in mind. Interview transcripts were analyzed using thematic analysis methods to identify concepts (specific symptoms/impacts) and themes (higher-level categories grouping related concepts). A cross-mapping exercise was performed between interview-identified concepts and items included in the AE-QoL. Results Fourteen patients were interviewed and included in the analysis (age range, 28–82 years [mean 47.5 years]; 64% female; 93% white). In 10 interviews, patients mentioned having no or nearly no HAE attacks, no longer feeling limited by HAE, less HAE-related anxiety/worry and depression, an improved ability to travel, fewer emergency room/hospital visits, and ease of administration of C1INH(SC), including not requiring assistance from others. Other commonly expressed concepts included: increased feelings of confidence, independence, optimism, and normalcy; less absence from work/school; better productivity; improved sleep and energy; healthier family relationships; and improved cognition. While all AE-QoL items emerged from patient interviews, a number of identified concepts were not addressed by the AE-QoL, including sensitivity to various potential attack-triggers (e.g., stress/anxiety, sports), attack frequency, not having to cancel social plans, improvements in ability to perform day-to-day tasks, and a lower burden from medical visits. Conclusions From these interviews, a large number of common themes and concepts emerged: a greater sense of freedom and normalcy, increased productivity, and improved interpersonal relationships while using convenient and effective prophylaxis. These findings provide insights into real-world experiences and the many facets of HRQoL that are important to patients with HAE-C1INH. |
topic |
Subcutaneous C1-inhibitor Hereditary angioedema Health-related quality of life Productivity HAEGARDA Qualitative research |
url |
https://doi.org/10.1186/s13223-021-00550-5 |
work_keys_str_mv |
AT johnanderson lettingthepatientsspeakanindepthqualitativeresearchbasedinvestigationoffactorsrelevanttohealthrelatedqualityoflifeinrealworldpatientswithhereditaryangioedemausingsubcutaneousc1inhibitorreplacementtherapy AT donaldslevy lettingthepatientsspeakanindepthqualitativeresearchbasedinvestigationoffactorsrelevanttohealthrelatedqualityoflifeinrealworldpatientswithhereditaryangioedemausingsubcutaneousc1inhibitorreplacementtherapy AT williamlumry lettingthepatientsspeakanindepthqualitativeresearchbasedinvestigationoffactorsrelevanttohealthrelatedqualityoflifeinrealworldpatientswithhereditaryangioedemausingsubcutaneousc1inhibitorreplacementtherapy AT patriciakoochaki lettingthepatientsspeakanindepthqualitativeresearchbasedinvestigationoffactorsrelevanttohealthrelatedqualityoflifeinrealworldpatientswithhereditaryangioedemausingsubcutaneousc1inhibitorreplacementtherapy AT sallylanar lettingthepatientsspeakanindepthqualitativeresearchbasedinvestigationoffactorsrelevanttohealthrelatedqualityoflifeinrealworldpatientswithhereditaryangioedemausingsubcutaneousc1inhibitorreplacementtherapy AT hhenryli lettingthepatientsspeakanindepthqualitativeresearchbasedinvestigationoffactorsrelevanttohealthrelatedqualityoflifeinrealworldpatientswithhereditaryangioedemausingsubcutaneousc1inhibitorreplacementtherapy |
_version_ |
1721319872539918336 |